晶泰控股宣布与一家领先的生物制药公司建立战略合作伙伴关系,双方将携手开发针对G蛋白偶联受体(GPCR)靶点的口服小分子治疗药物。此次合作旨在结合晶泰控股在人工智能驱动药物研发平台方面的技术优势,与合作伙伴在药物开发和商业化领域的专长,共同推进创新疗法的发现与开发进程。
晶泰控股宣布与一家领先的生物制药公司建立战略合作伙伴关系,双方将携手开发针对G蛋白偶联受体(GPCR)靶点的口服小分子治疗药物。此次合作旨在结合晶泰控股在人工智能驱动药物研发平台方面的技术优势,与合作伙伴在药物开发和商业化领域的专长,共同推进创新疗法的发现与开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.